Opportunity Information: Apply for RFA DA 25 047
The National Institutes of Health (NIH) is offering a discretionary grant opportunity titled "Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)" under Funding Opportunity Number RFA-DA-25-047. This program is designed specifically for small business concerns (SBCs) that want to develop and ultimately commercialize products or technologies aimed at addressing health-related social needs that contribute to or worsen substance use disorders. A key boundary in the scope is that the focus is on substance use disorders excluding alcohol use disorder, so proposals should be centered on other substances and the associated use disorders.
This funding opportunity uses the NIH Small Business Innovation Research (SBIR) phased mechanism, reflected in the R41/R42 activity codes. In practical terms, R41 generally corresponds to an early, feasibility and proof-of-concept stage (Phase I), while R42 supports further development and validation steps that move a technology closer to commercialization (Phase II). The notice also indicates that a clinical trial is optional, meaning applicants can propose projects that do or do not include a clinical trial component, depending on what is appropriate for the product being developed and the evidence needed to advance it toward market readiness.
The central theme is the development of technologies that address "health-related social needs" affecting people with SUD. While the specific examples and allowable approaches are detailed in the full Notice of Funding Opportunity, this framing typically points to practical, product-oriented solutions that reduce barriers and improve outcomes where social conditions influence health and recovery. The intent is not simply to study social needs in the abstract, but to produce a technology with a clear pathway to real-world use and commercialization that can mitigate social factors that interfere with treatment, retention, recovery supports, or broader health stability for people living with SUD.
Eligibility is limited primarily to small businesses. Non-domestic (non-U.S.) entities, including foreign institutions, are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible. However, the opportunity notes that "foreign components," as defined under the NIH Grants Policy Statement, may be allowed, which typically means some aspects of the work may involve foreign collaborations or activities if they meet NIH policy requirements and are well-justified, though the applicant organization itself must meet the domestic eligibility rules described in the announcement.
Administratively, this opportunity is issued by the NIH and is categorized under education and health, with CFDA number 93.279. The original closing date listed is March 13, 2026, which is the key deadline applicants should plan around unless the NIH posts updates or additional receipt dates in the full announcement. The listed award ceiling is $295,924, indicating the maximum amount expected per award under the terms associated with this listing. The source data also lists "ExpectedAwards" without a number, suggesting the total number of awards may depend on available funds, application volume, and merit as determined through NIH review and funding decisions.
Overall, the program is best read as an SBIR commercialization-focused opportunity from NIH for U.S.-eligible small businesses to build practical, deployable products that address social-need-related barriers affecting non-alcohol substance use disorders, with flexibility to include clinical trial work when it fits the development plan. For the most accurate requirements around project scope, budget structure by phase, application components, review criteria, and any specific priority areas or examples of responsive technologies, applicants would need to rely on the full Notice of Funding Opportunity referenced in the posting.Apply for RFA DA 25 047
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2023-09-28.
- Applicants must submit their applications by 2026-03-13. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $295,924.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this NIH funding opportunity?
The opportunity is titled "Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-DA-25-047.
Which agency is offering this grant?
This opportunity is offered by the National Institutes of Health (NIH).
What type of grant mechanism is being used?
This uses the NIH Small Business Innovation Research (SBIR) phased mechanism with activity codes R41/R42. In general, R41 aligns with Phase I (feasibility/proof of concept) and R42 aligns with Phase II (further development/validation toward commercialization).
Who is this opportunity designed for?
It is designed specifically for small business concerns (SBCs) that want to develop and ultimately commercialize products or technologies.
What is the main purpose of the program?
The program supports the development of products or technologies that address health-related social needs that contribute to or worsen substance use disorders (SUD), with an emphasis on real-world use and commercialization rather than abstract study.
What does "health-related social needs" mean in this context?
Based on the description provided, it refers to social conditions that influence health and recovery and can create barriers to treatment, retention, recovery supports, or broader health stability for people living with SUD. The program emphasis is on practical, product-oriented solutions that mitigate these social-need-related barriers.
Is alcohol use disorder included in the scope?
No. The scope is focused on substance use disorders excluding alcohol use disorder, so proposals should address other substances and the associated use disorders.
Does the project have to include a clinical trial?
No. The funding opportunity states "Clinical Trial Optional," meaning applicants may propose projects with or without a clinical trial component, depending on what fits the product development plan and evidence needs.
Is this opportunity focused on research or commercialization?
The framing is SBIR and commercialization-focused. The intent is to produce a technology with a clear pathway to real-world use and commercialization that addresses social-need-related factors impacting SUD outcomes.
What are the R41 and R42 phases intended to support?
R41 generally corresponds to Phase I activities such as feasibility and proof-of-concept work. R42 generally supports Phase II activities such as further development and validation steps that move the technology closer to commercialization.
Are non-U.S. organizations eligible to apply?
No. Non-domestic (non-U.S.) entities, including foreign institutions, are not eligible to apply.
Can a U.S. organization include non-domestic components?
No. Non-domestic components of U.S. organizations are also not eligible under the description provided.
Are any foreign activities allowed at all?
The opportunity notes that "foreign components," as defined under the NIH Grants Policy Statement, may be allowed. This typically means certain well-justified foreign collaborations or activities could be permissible under NIH policy, while the applicant organization itself must still meet the domestic eligibility requirements.
What is the CFDA number for this opportunity?
The CFDA number listed is 93.279.
How is this opportunity categorized?
It is categorized under education and health.
What is the application deadline?
The original closing date listed is March 13, 2026. Applicants should also watch for any updates or additional receipt dates that NIH may post in the full announcement.
What is the maximum award amount (award ceiling)?
The listed award ceiling is $295,924, indicating the maximum amount expected per award under the terms associated with this listing.
How many awards will NIH make?
The source data lists "ExpectedAwards" without a number. That suggests the total number of awards may depend on available funds, the number of applications received, and merit as determined through NIH review and funding decisions.
What kinds of projects are likely to be considered responsive?
Based on the description provided, responsive projects would be those that develop practical, deployable products or technologies that address health-related social needs affecting people with SUD, with a clear plan to move toward real-world adoption and commercialization. Specific examples and allowable approaches are stated to be in the full Notice of Funding Opportunity.
Where should applicants look for the most authoritative requirements and details?
For exact requirements on scope, budget structure by phase, application components, review criteria, and any specific priority areas or examples of responsive technologies, applicants should rely on the full Notice of Funding Opportunity referenced in the posting.
Browse more opportunities from the same category: Education, Health
Next opportunity: Research in Basic Plasma Science and Engineering
Previous opportunity: Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)?
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 25 047
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 25 047) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional) Apply for RFA DA 24 033 Funding Number: RFA DA 24 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required) Apply for RFA DA 24 032 Funding Number: RFA DA 24 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) Apply for PAR 23 276 Funding Number: PAR 23 276 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Advancing Research Careers (ARC) Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00 - Clinical Trial Not Allowed) Apply for PAR 23 222 Funding Number: PAR 23 222 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Pre-Cancer Atlas (PCA) Research Centers (U01 Clinical Trial Not Allowed) Apply for RFA CA 23 040 Funding Number: RFA CA 23 040 Agency: National Institutes of Health Category: Education, Health Funding Amount: $800,000 |
| Single Source: Human Tumor Atlas Network Data Coordinating Center (HTAN-DCC; U24 Clinical Trial Not Allowed) Apply for RFA CA 23 041 Funding Number: RFA CA 23 041 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,800,000 |
| Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) Apply for RFA DA 25 059 Funding Number: RFA DA 25 059 Agency: National Institutes of Health Category: Education, Health Funding Amount: $459,000 |
| Human Tumor Atlas (HTA) Research Centers (U01 Clinical Trial Not Allowed) Apply for RFA CA 23 039 Funding Number: RFA CA 23 039 Agency: National Institutes of Health Category: Education, Health Funding Amount: $800,000 |
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 011 Funding Number: RFA DA 25 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional) Apply for PAR 23 308 Funding Number: PAR 23 308 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,700,000 |
| Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) Apply for PAR 24 047 Funding Number: PAR 24 047 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required) Apply for PAR 23 304 Funding Number: PAR 23 304 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Apply for PAR 23 303 Funding Number: PAR 23 303 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional) Apply for RFA CA 24 006 Funding Number: RFA CA 24 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Applying Imaging Pipelines for Spatial Characterization of Cellular Interactions in HIV-related CNS Pathology and/or Substance Use (R61/R33 Clinical Trial Not Allowed) Apply for RFA DA 24 030 Funding Number: RFA DA 24 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 012 Funding Number: RFA DA 25 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed) Apply for RFA DA 25 013 Funding Number: RFA DA 25 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional) Apply for RFA DA 25 052 Funding Number: RFA DA 25 052 Agency: National Institutes of Health Category: Education, Health Funding Amount: $295,924 |
| Tools for Decentralized Clinical Trials for Substance Use Disorder (R41/R42 Clinical Trials Optional) Apply for RFA DA 25 051 Funding Number: RFA DA 25 051 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,972,828 |
| Resource Center for Cannabis and Cannabinoid Research (U24 Clinical Trial Not Allowed) Apply for RFA AT 24 006 Funding Number: RFA AT 24 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: $850,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 25 047", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.